Telencephalic morphogenesis is impaired in Ftm/Rpgrip1l KO mice

por Laclef, C, Catala, M, Anselme, I, Besse, L, Schneider-Maunoury, S
Publicado 2012

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways

por Besse, L, Kraus, M, Besse, A, Bader, J, Silzle, T, Mehrling, T, Driessen, C
Publicado 2017

Rescue of corpus callosum agenesis in two ciliary mutants by the short repressor isoform of Gli3

por Laclef, C, Anselme, I, Besse, L, Catala, M, Baas, D, Paschaki, M, Durand, B, Schneider-Maunoury, S
Publicado 2015

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado 2018

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

por Hitz, F., Kraus, M., Pabst, T., Hess, D., Besse, L., Silzle, T., Novak, U., Seipel, K., Rondeau, S., Stüdeli, S., Vilei, S. Berardi, Samaras, P., Mey, U., Driessen, C.
Publicado 2019

Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism

por Soriano, G P, Besse, L, Li, N, Kraus, M, Besse, A, Meeuwenoord, N, Bader, J, Everts, B, den Dulk, H, Overkleeft, H S, Florea, B I, Driessen, C
Publicado 2016

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY C...

por Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L.
Publicado 2023